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Summary
In a large‐scale study, 128176 non‐pregnant patients (228 studies) and 10000
pregnant patients (121 studies) confirmed COVID‐19 cases included in this Meta‐
Analysis. The mean (confidence interval [CI]) of age and gestational age of
admission (GA) in pregnant women was 33 (28–37) years old and 36 (34–37)
weeks, respectively. Pregnant women show the same manifestations of COVID‐19
as non‐pregnant adult patients. Fever (pregnant: 75.5%; non‐pregnant: 74%) and
cough (pregnant: 48.5%; non‐pregnant: 53.5%) are the most common symptoms in
both groups followed by myalgia (26.5%) and chill (25%) in pregnant and dysgeusia
(27%) and fatigue (26.5%) in non‐pregnant patients. Pregnant women are less
probable to show cough (odds ratio [OR] 0.7; 95% CI 0.67–0.75), fatigue (OR: 0.58;
CI: 0.54–0.61), sore throat (OR: 0.66; CI: 0.61–0.7), headache (OR: 0.55; CI:
0.55–0.58) and diarrhea (OR: 0.46; CI: 0.4–0.51) than non‐pregnant adult patients.
The most common imaging found in pregnant women is ground‐glass opacity (57%)
and in non‐pregnant patients is consolidation (76%). Pregnant women have higher
proportion of leukocytosis (27% vs. 14%), thrombocytopenia (18% vs. 12.5%) and
have lower proportion of raised C‐reactive protein (52% vs. 81%) compared with
non‐pregnant patients. Leucopenia and lymphopenia are almost the same in both
groups. The most common comorbidity in pregnant patients is diabetes (18%) and
in non‐pregnant patients is hypertension (21%). Case fatality rate (CFR) of non‐
pregnant hospitalized patients is 6.4% (4.4–8.5), and mortality due to all‐cause for
pregnant patients is 11.3% (9.6–13.3). Regarding the complications of pregnancy,
postpartum hemorrhage (54.5% [7–94]), caesarean delivery (48% [42–54]),
preterm labor (25% [4–74]) and preterm birth (21% [12–34]) are in turn the most
Abbreviations: ACE2, angiotensin‐converting enzyme 2; BMI, body mass index; CDC, Centers for Disease Control and Prevention; CFR, case fatality rate; CI, confidence interval; COVID‐
19, coronavirus disease 2019; CRP, C‐reaction protein; CT scan, computed tomography scan; ESR, erythrocyte sedimentation rate; GA, gestational age; GGO, ground‐glass opacity; IQR,
interquartile range; LBW, low birth weight; LDH, lactate dehydrogenase; MERS‐CoV, Middle East respiratory syndrome coronavirus; N, number; NA, not known; NICU, newborn intensive
care unit; OR, odds ratio; PPH, postpartum haemorrhage; PRISMA, Preferred Reporting Items for systematic Reviews and Meta‐analysis Statement; RT‐PCR, real‐time polymerase chain
reaction; SARS‐CoV, severe acute respiratory syndrome coronavirus; WBC, white blood cell.
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prevalent complications. Comparing the pregnancy outcomes show that caesarean
delivery (OR: 3; CI: 2–5), low birth weight (LBW) (OR: 9; CI: 2.4–30) and preterm
birth (OR: 2.5; CI: 1.5–3.5) are more probable in pregnant woman with COVID‐19
than pregnant women without COVID‐19. The most prevalent neonatal compli-
cations are neonatal intensive care unit admission (43% [2–96]), fetal distress (30%
[12–58]) and LBW (25% [16–37]). The rate of vertical transmission is 5.3%
(1.3–16), and the rate of positive SARS‐CoV‐2 test for neonates born to mothers
with COVID‐19 is 8% (4–16). Overall, pregnant patients present with the similar
clinical characteristics of COVID‐19 when compared with the general population,
but they may be more asymptomatic. Higher odds of caesarean delivery, LBW and
preterm birth among pregnant patients with COVID‐19 suggest a possible asso-
ciation between COVID‐19 infection and pregnancy complications. Low risk of
vertical transmission is present, and SARS‐CoV‐2 can be detected in all conception
products, particularly placenta and breast milk. Interpretations of these results
should be done cautiously due to the heterogeneity between studies; however, we
believe our findings can guide the prenatal and postnatal considerations for
COVID‐19 pregnant patients.
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1 | INTRODUCTION
Major human pathogenic coronaviruses are severe acute respiratory
syndrome coronavirus 1 (SARS‐CoV‐1), Middle East respiratory
syndrome coronavirus (MERS‐CoV) and the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2).1 Horizontal transmission of
SARS‐CoV‐2 occurs via aerosolized droplets or through contact with
infected surfaces, potentially leading to the coronavirus disease 2019
(COVID‐19).2 SARS‐CoV‐2 is more contiguous than SARS‐CoV‐1 and
MERS‐CoV.3 All demographics are susceptible to SARS‐CoV‐2;
pregnant women are no exception. Respiratory and immune system
adaptations during pregnancy increase the risk of acquiring pneu-
monia and developing severe complications.4,5 Pregnancy makes
women more susceptible to severe infection by infectious agents
such as influenza virus.6 Influenza vaccine was shown to decrease
birth outcomes involving preterm birth and low birth weight
(LBW).7 To protect the fetus from maternal immune responses, al-
terations in the immune system are necessary, which include
decreased number and activity of T cells (both CD4+ and CD8+) and
natural killer cells and decreased T‐cell proliferation,8–10 as well as
pregnancy‐related hormones that are speculated to weaken cellular
immunity. 11 Cardiopulmonary alterations such as increased heart
rate and stroke volume and decreased residual capacity may also play
an important role in vulnerability of pregnant women to respiratory
infections. Decreased functional residual capacity occurs due to
anatomical changes in diaphragm and thorax and stimulation of the
central respiratory centre via hormonal changes, such as increased
corticosteroid aimed at increasing ventilation, but they can cause
hypoxia and decreased respiratory capacity in an acute lung injury
such as pneumonia.12
SARS‐CoV‐1 was linked to complications related to severe
infection and a higher mortality rate in pregnant women compared to
non‐pregnant patients.13,14 Similarly, an increased risk for severe
COVID‐19 among pregnant women compared with non‐pregnant
women has also been reported.15 SARS‐CoV‐1 was also reported to
cause obstetric complications such as spontaneous abortion, preterm
delivery and intrauterine growth restriction.13,16 Of note, animal
models evidenced that expression and activity of angiotensin‐con-
verting enzyme 2 (ACE2), the main receptor for SARS‐CoV‐2, increase
in kidney, uterus and placenta during pregnancy.17 Thus, it can be
hypothesized that reproductive organs are potential targets for SARS‐
CoV‐2. Impact of SARS‐CoV‐2 infection on pregnancy outcomes have
not been consistently reported. Women infected with SARS‐CoV‐2
were reported to show elevated rates of obstetric complications such
as caesarean delivery and preterm birth.18,19 However, there are re-
ports that indicated no significant difference between SARS‐CoV‐2
infection and adverse outcomes of pregnancy.20,21 By conducting a
large‐scale meta‐analysis of reports on SARS‐CoV‐2 infection, we
aimed to provide comprehensive data regarding pregnant patients.
We quantified clinical, laboratory and imaging features of the SARS‐
CoV‐2 infection in addition to pregnancy‐related characteristics and
outcomes of pregnant women. To assess the impact of SARS‐CoV‐2 on
pregnancy, comparison between pregnant women and control groups
was performed, whenever data were available.
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Another concern is the vertical transmission from the mother
to the fetus or neonate during perinatal period that needs to be
addressed. Since the beginning of the SARS‐CoV‐2 outbreak,
several studies have been published regarding mother‐to‐infant
transmission,22–25 but the risk of vertical transmission in the pop-
ulation is not clear. This lack of knowledge and subsequent anxiety
in patients and clinicians might be an explanation for the high
prevalence of preterm birth and caesarean delivery in COVID‐19
patients.26,27 In this study, data are provided regarding the rate of the
vertical transmission, SARS‐CoV‐2 detection in neonates born to
infected mothers, and viral detection in breast milk and conception
products.
2 | METHODS
2.1 | Search strategy
This study was conducted according to the Preferred Reporting Items
for Systematic Reviews and Meta‐Analyses Statement guidelines.28
We searched all studies published up to October 2020, from the
following databases: Embase, Scopus, PubMed, Web of Science and
the Cochrane library. Search medical subject headings terms used
were ‘COVID‐19’, ‘SARS Cov‐2’, ‘severe acute respiratory syndrome
coronavirus 2’, ‘coronavirus disease 2019 virus’, ‘ 2019 novel coro-
navirus’, ‘COVID‐19’, ‘ pregnant’, ‘pregnancy’ and all their synonyms
like ‘SARS‐CoV‐2’ and ‘2019‐nCoV’. Moreover, we searched for un-
published and grey literature with Google scholar, Centers for Dis-
ease Control and Prevention (CDC) and World Health Organization
databases. We also examined references of included articles to find
additional relevant studies. There was no language restriction, and all
other languages were translated by https://translate.google.com/.
Additional search strategy details are provided in Table S1.
2.2 | Study selection
Duplicate studies were removed using EndNote X7 (Thomson Reu-
ters). Records were initially reviewed by title and abstract indepen-
dently by three authors (AP, SG and MR). The full text of potentially
eligible records was retrieved and examined, and any disagreement
was resolved by consensus.
2.3 | Eligibility and inclusion criteria
Studies to be eligible for inclusion in our meta‐analysis had to have
the following predetermined criteria. All case–control, cross‐
sectional, cohort studies, case reports and case‐series peer‐reviewed
studies were included if they reported the number of confirmed cases
of patients with demographic data, [AND] [OR] clinical data, [AND]
[OR] radiology data, [AND] [OR] laboratory data [AND] [OR]
risk factor data. Only patients with laboratory confirmation of
SARS‐CoV‐2 infection were included. In all included case–control
studies, ‘pregnant women with confirmed COVID‐19’ were the case
group. Two different types of control groups were included and
analysed as follows: (1) non‐pregnant patients (either genders) with
COVID‐19 and (2) pregnant women without COVID‐19.
2.4 | Exclusion criteria
Studies without the number of confirmed cases, letters to editor,
review articles, individual case reports and news reports were
excluded. Duplicate data from the same patients were combined and
counted as a single case when the data were reported more than one.
2.5 | Data extraction
All included literatures were published in 2020. The following items
were extracted from each article: first author, centre and study
location, countries, sample collection time, patient follow‐up time, the
reference standard for infection confirmation, number of confirmed
cases, study type, and all demographic, clinical, radiological, labora-
tory data, and risk factor data. Two of our authors (SG and MR)
independently extracted data, and all extracted data were checked
randomly by another author (AP); the differences were resolved by
consensus.
2.6 | Quality assessment
Quality assessments of studies were performed by two reviewers
independently according to the Critical Appraisal Checklist recom-
mended by the Joanna Briggs Institute, and disagreements were
resolved by consensus. The checklist is composed of nine questions
that reviewers addressed for each study. The ‘Yes’ answer to each
question received one point. Thus, the final scores for each study
could range from 0 to 9 (Table S2).29
2.7 | Analysis
Data cleaning and preparation were done in Microsoft Excel 2010
(Microsoft©), and further analyses were carried out via Compre-
hensive Meta‐Analysis Software Version 2.0 (Biostat). Determination
of heterogeneity among the studies was undertaken using the chi‐
squared test (Cochran's Q) to assess the appropriateness of pooling
data. We used random‐effect model (M‐H heterogeneity) for pooled
proportion results.30 Pooled odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated from the raw data of the included
studies using the random‐effects models. Percentages and
means ± standard deviations (SDs) were calculated to describe the
distributions of categorical and continuous variables, respectively.
p‐Values reflect study heterogeneity with <0.05 being significant.
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We also used the funnel plot, Begg's and Egger's tests based on the
symmetry assumption to detect publication bias (Figure S1).
3 | RESULTS
3.1 | Characteristics of included studies
The process of study selection is represented in Figure 1. A total of
551,755 reports were screened for the analysis of patients with non‐
pregnant COVID‐19 and pregnant COVID‐19; 545,031 of them were
excluded after the duplicate removing, title and abstract screening;
and the full text of 497 reports were reviewed in full text. We
excluded studies that did not report sufficient data such as variables
that we were looking for. Out of 349 included studies, 228 studies
met the inclusion criteria for non‐pregnant COVID‐19 and 121 for
pregnant COVID‐19. The characteristics of the selected articles are
summarized in Table S3.
3.2 | Quality assessment
Quality assessment of included studies was performed based on the
Critical Appraisal Checklist, and the final quality scores of the
included studies are represented in Table S2. Among 349 included
studies, 155 had high quality (8–9 score), 117 medium (6–7 score),
and 77 study had low (score 5) or unknown quality. For example,
studies by Chen,31 Wang,32 Huang,33 Guan,34 Zhang,35 Cheng,36 Li,37
Xu38 and Song39 had the highest quality of the COVID‐19 studies
available to date in the purpose of this study.
F I GUR E 1 Flow diagram of literature search and study selection (PRISMA flow chart)
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3.3 | Demographics, baseline characteristics and
clinical characterization
Overall, 128,176 non‐pregnant patients with confirmed COVID‐19
infection and 10,000 pregnant COVID‐19 patients were included in
the meta‐analysis. Funnel plots for included studies did not detect
significant publication bias (Figure S1). The mean age among 125,360
non‐pregnant COVID‐19 patients, was 51.2 (95% CI 45–57,
p < 0.001), and was 33 (95% CI 28–37, p < 0.001) among 3348
pregnant COVID‐19 patients.
Table 1 shows that most non‐pregnant COVID‐19 was 74% (95%
CI 72.5–79, p < 0.001), and pregnant COVID‐19 75.5% (95% CI
36–58, p < 0.001) had fever. Cough was the second most common
symptom presenting in both non‐pregnant COVID‐19 53.5% (95% CI
50–58, p < 0.001) and pregnant COVID‐19 48.5% (95% CI 42–55,
p < 0.001) patients. Myalgia was the third most common manifes-
tation in pregnant COVID‐19 26.5% (95% CI 19–35, p < 0.001).
Dysgeusia was the third most common symptom presenting in
non‐pregnant COVID‐19 27% (95% CI 10–53, p = 0.9). Also, fatigue
was the fourth most common symptom in non‐pregnant COVID‐19
26.5% (95% CI 24–30, p < 0.001), while it was less common in
pregnant COVID‐19 21% (95% CI 17–25.5, p < 0.001) patients. Chill
was the fourth most common symptom detected in 25% (95% CI
17–87, p = 0.03) of pregnant patients. Anosmia was found in 25%
(95% CI 11–48, p = 0.9) of non‐pregnant COVID‐19, while it is found
in 13.5% (95% CI 5–31.5, p < 0.001) of pregnant COVID‐19 patients.
The mean body temperature was 37.2 (95% CI 37.1–37.3, p = 0.1)
among non‐pregnant COVID‐19 patients, and it was 36.7 (95% CI
33–38.5, p < 0.001) among pregnant COVID‐19 patients. Hemoptysis
was found in 3% (95% CI 1.5–4.5, p < 0.001) among non‐pregnant
COVID‐19 patients, and it was found in 3.5% (95% CI 0.5–19
p = 0.07) among pregnant COVID‐19 patients.
3.4 | Risk factors and comorbidities of patients
infected with COVID‐19
Totally, 41% (95% CI 35–52, p < 0.001) of non‐pregnant COVID‐19
patients and 35% (95% CI 20–54, p < 0.001) of pregnant COVID‐19
had contact with another person with respiratory symptoms. Another
risk factor for non‐pregnant COVID‐19 was health care worker by
22.5% (95% CI 9–43, p < 0.001), in comparison to 17% (95% CI
6.5–31, p = 0.02) in pregnant COVID‐19. The most common co-
morbidity for non‐pregnant COVID‐19 was hypertension in 21%
(95% CI 16–25, p < 0.001), in comparison to 9% (95% CI 8–10,
p < 0.001) in pregnant COVID‐19. Diabetes was the most common
comorbidity for pregnant COVID‐19 in 18% (95% CI 11–27, p = 0.4)
in comparison to non‐pregnant COVID‐19 was 11% (95% CI 7.5–
14.5, p < 0.001). In addition, non‐gestational diabetes and gestational
diabetes among pregnant patients with COVID‐19 were 8% (95% CI
4.5–13, p < 0.001) and 10% (95% CI 7.5–13.5, p = 0.07), respectively.
Bacterial co‐infection occurred in non‐pregnant COVID‐19 in 4.3%
(95% CI 1.4–11, p < 0.001), compared to 16% (95% CI 2.5–61,
p < 0.001) in pregnant COVID‐19. Viral co‐infection occurred in non‐
pregnant COVID‐19 in 4.5% (95% CI 2–11, p < 0.001) patients, when
compared to pregnant COVID‐19 14% (95% CI 7.5–25, p = 0.6).
3.5 | Chest x‐ray and CT scan findings in non‐
pregnant and pregnant patients with COVID‐19
The analysis showed that 83.5% (95% CI 77–80, p < 0.001) of non‐
pregnant COVID‐19 patients and 89% (95% 75–95, p < 0.001) of
pregnant COVID‐19 patients had abnormal radiological findings on
chest x‐ray or computed tomography (CT) scan. The most common
radiological abnormalities in non‐pregnant COVID‐19 patients were
77.2% (95% CI 61.5–86, p < 0.001) bilateral involvement, 76% (95%
CI 50.5–91, p < 0.001) consolidation and 72% (95% CI 41–92,
p < 0.001) ground‐glass opacities (GGOs). The most common radio-
logical abnormalities in pregnant COVID‐19 were 68% (95% CI
54–79, <0.001) bilateral involvement, 57% (95% CI 39–73,
p < 0.001) GGO and 41% (95% CI 30–53, p < 0.001) consolidation.
Also, abnormal chest x‐ray findings in neonates were found in 49%
(95% CI 13–41, p = 0.09) (Table 1).
3.6 | Outcome
Based on the available data, the case fatality rate (CFR) of non‐
pregnant COVID‐19 hospitalized patients was 6.4% (95% CI 4.4–8.5,
p < 0.001). For pregnant patients, the CFR was not possible to report
based on the original article; however, death from all‐cause in
pregnant women with COVID‐19 was calculated 11.3% (95% CI
9.6–13.3, I2 82%).
3.7 | Association of clinical outcomes and
laboratory findings between case and control groups
Table 2 shows odds ratio (OR) for comparing clinical symptoms of
COVID‐19 between pregnant patients (cases) and non‐pregnant
(controls). Pregnant patients were less probable to present some of
the common manifestations of COVID‐19 comparing with non‐
pregnant patients including cough (OR = 0.7, CI 0.67–0.75, I2 = 85),
sore throat (OR = 0.66, CI 0.61–0.7, I2 = 82), headache (OR = 0.55, CI
0.55–0.58, I2 = 65), fatigue (OR = 0.58, CI 0.54–0.61, I2 = 91) and
diarrhoea (OR = 0.46, CI 0.4–0.51, I2 = 87). Odds of fever and nausea
and vomiting, on the other hand, were not significant between
groups. Table 2 also shows OR for clinical outcomes for comparison
between COVID‐19 pregnant patients (cases) and non‐COVID‐19
pregnant patients (controls). Caesarean delivery was significantly
higher in COVID‐19 patients by yielding a summary OR of 3 (95% CI
2–5, I2 = 28), same as preterm birth with OR of 2.5 (95% CI 1.5–3.5,
I2 = 0) and LBW with OR of 9 (95% CI 2.4–30, I2 = 0).
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TAB L E 1 Demographics and clinical manifestations of COVID‐19 in pregnant women compared with non‐pregnant adult patients with
confirmed SARS‐CoV‐2 infection
Variables






















Age (years)* 51.2 (45–57) 189 125,360 98 <0.001 33 (28–37) 56 3348 98 <0.001
Male sex 52.2 (50–53.2) 216 127,743 81 <0.001 ‐ ‐ ‐ ‐ ‐
Fever 74 (72.5–79) 182 125,237 89 <0.001 75.5 (36–58) 55 3302 75 <0.001




37.2 (37.1–37.3) 28 7691 53 0.01 36.7 (mean)(35–38.5) 27 159 99 <0.001
Fatigue 26.5 (24–30) 163 121,645 92 <0.001 21 (17–25.5) 25 2030 66 <0.001
Myalgia 19.5 (17–24) 145 97,077 91 <0.001 26.5 (19–35) 18 1196 79 <0.001
Dyspnea 14.5 (11–19) 124 78,761 89 <0.001 22 (16–28) 26 2306 85 <0.001
Cough 53.5 (50–58) 183 125,162 89 <0.001 48.5 (42–55) 52 3175 84 <0.001
Sputum 19.5 (18–24) 134 81,506 81 <0.001 13 (5–31.5) 13 1209 93 <0.001
Sore throat 10.5 (9.5–14) 98 57,989 89 <0.001 9 (6–14) 10 313 0 0.7
Dysgeusia 27 (10–53) 14 1023 0 0.9 6 (3–10) 7 221 0 0.09
Anosmia 25 (11–48) 18 1220 0 0.9 13.5 (5–31.5) 9 1240 90 <0.001
Headache 11 (9–12) 121 72,311 81 <0.001 16 (6–46) 8 240 69 0.02
Chest pain 11 (8–12.5) 78 47,759 89 <0.001 13 (9–19) 13 216 0 0.09
Diarrhoea 8 (6.6–11) 131 81,421 93 <0.001 9 (6–12.5) 28 2523 73 <0.001
Nausea and
vomiting
4 (4–8.5) 81 52,878 89 <0.001 11 (7–18) 11 954 75 <0.001
Hemoptysis 3 (1.5–4.5) 28 7754 71 <0.001 3.5 (0.5–19) 7 696 69 0.07
Renal injury 9.5 (6–14.5) 58 6577 92 <0.001 3 (1–9.5) 12 1381 73 0.09
























41 (35–52) 65 11,126 94 <0.001 35 (20–54) 26 8365 69 <0.001
Healthcare
worker
22.5 (9–43) 43 89,657 92 <0.001 17 (6.5–31) 5 129 66 0.02
Hypertension 21 (16–25) 146 17,451 94 <0.001 b9 (8–10) 24 8328 96 <0.001
Diabetes 11 (7.5–14.5) 103 96,545 94 <0.001 c18 (11–27) 21 8267 0 0.4
Non‐gestational
diabetes
‐ ‐ ‐ ‐ ‐ 8 (4.5–13) 26 8412 82 <0.001
Gestational
diabetes




10.5 (7–14.5) 87 86,678 96 <0.001 6.3 (4–10) 14 8064 93 <0.001
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T A B L E 1 (Continued)
























4.3 (1.4–11) 31 3767 89 <0.001 16 (2.5–61) 18 5467 84 <0.001
Viral co‐
infection
4.5 (2–11) 28 5876 84 <0.001 14 (7.5–25) 17 5134 0 0.6

























83.5 (77–80) 29 3765 89 <0.001 89 (75–95) 38 3361 96 <0.001
Bilateral
involvement
77.2 (61.5–86) 35 86,156 91 <0.001 68 (54–79) 22 1477 85 <0.001
Unilateral
involvement
16 (12–21.5) 63 8434 89 <0.001 24 (21–27) 14 1387 14 0.31
Consolidation 76 (50.5–91) 16 3454 91 <0.001 41 (30–53) 9 771 85 <0.001
Ground‐glass
opacity


























6.4 (4.4–8.5) 153 98,987 89 <0.001 11.3 (9.6–13.3) 18 2660 82 <0.001
Abbreviations: CI, confidence interval; NA, not available; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
aContact with another person with respiratory symptoms.
bIncluding both gestational and chronic hypertension.
cIncluding both gestational and non‐gestational diabetes.
dFor pregnant women, maternal death from all‐cause is reported
*Age and body temperature are presented in mean. Other variables are reported as proportions.
**Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity.
***A low p‐value (<0.05) is consistent with high heterogeneity.
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Pregnant Women with COVID‐19
(Case) n/N
Non‐pregnant patients with COVID‐19
(Control) n/N
Fever 0.8 (0.6–1.1) 5 95 <0.001 4562/31,871 87,090/470,092
Cough 0.7 (0.67–0.75) 5 85 <0.001 23,114/241,238 41,570/121,240
Sore throat 0.66 (0.61–0.7) 5 82 <0.001 543/14,238 1682/41,240
Headache 0.55 (0.55–0.58) 5 65 0.007 2710/14,138 41,899/121,240
Fatigue 0.58 (0.54–0.61) 5 91 <0.001 1929/13,238 30,505/98,240
Diarrhoea 0.46 (0.4–0.51) 4 87 <0.001 872/14,138 18,121/142,240
Nausea and
vomiting







Pregnant women with COVID‐19
(Case) n/N




1.3 (0.87–1.9) 5 0 0.9 36/638 120/2671
Singleton 0.11 (−0.2–0.68) 3 0 0.4 118/121 414/415
Medical
comorbidities
8.4 (0.7–92) 3 49 0.16 4/32 5/242
Preterm birth 2.5 (1.5–3.5) 8 0 0.8 45/295 694/12,634
Low birth weight 9 (2.4–30) 2 0 0.99 6/32 6/242
Fetal distress 2.7 (0.6–9) 2 0 0.99 4/32 12/242
Caesarean delivery 3 (2–5) 7 28 0.21 179/257 6399/12,060
Lab findings





Pregnant women with COVID‐19
(Case) n/N
Pregnant Women without COVID‐19
(Control) n/N
Leucocyte (mean) 0.7 (0.3–1) 2 0 0.54 32 242
Neutrophil (mean) 0.53 (0.15–0.9) 2 0 0.4 32 242
Lymphocyte (mean) 0.4 (0.15–0.8) 2 0 0.6 32 242
Lymphocytes
decreased*
1 (0.3–3) 2 0 0.9 4/32 29/242
CRP (mean) 0.37 (0.01–0.7) 2 0 0.4 32 242
CRPIncreased* 0.4 (0.2–0.9) 2 0 0.65 10/32 125/242
ALT (mean) 0.05 (−0.36–0.4) 2 0 0.9 32 242
AST (mean) 0.3 (0.02–0.9) 2 0 0.56 32 242
Note: Different case and control groups. n; number of patients in each group who presented the variable of interest. N; total number of patients in each
group.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C‐reaction protein, n = number of variable, N= number of total
case or control; PMH, past medical history.
*Increased or decreased refers to values above or below the normal range.
**Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity.
***A low p‐value (<0.05) is consistent with high heterogeneity.
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3.8 | Laboratory findings of patients infected with
COVID‐19
The laboratory findings showed that among non‐pregnant COVID‐19
patients where data were available, mean count of leucocytes (white
blood count [WBC]) was 6 � 10⁹ per L (95% CI 5–7.2) which is less
than pregnant COVID‐19 that was 8 � 10⁹ per L (95% CI 7.2–8.8).
Also, the WBC was increased in 14% of non‐pregnant patients and
27% of pregnant COVID‐19 cases. WBC count was decreased in
25.5% of non‐pregnant patients which was almost the same as in
pregnant patients. Among non‐pregnant COVID‐19 patients, the
mean count of neutrophil was 4.3 � 10⁹ per L (95% CI 3.5–8.5), which
was less than pregnant COVID‐19, 6.6 � 10⁹ per L (95% CI 4.6–8.2).
The platelet count was decreased in 12.5% and 18% of non‐pregnant
and pregnant patients, respectively. D‐dimer level was elevated in
both groups, but it was higher in pregnant (3.5 mcg/ml, 95% CI:
1.4–5.5) than non‐pregnant (2.5 mcg/ml, 95% CI: 0.8–5.5). C‐reactive
protein (CRP) was increased in 81% and 52% of non‐pregnant and
pregnant patients, respectively (Table 3).
3.9 | Maternal characteristics and outcomes of
pregnant patients with confirmed COVID‐19
Medical comorbidities were present in 33% (95% CI 20–48,
p < 0.001) of mothers, history of caesarean delivery in 17% (95% CI
9.6–28, p = 0.3), the mean number of gravidity was 4.3 (95% CI 3.2–
5.5, p < 0.7), parity in 46% in a group of 864 pregnant women (95% CI
40–52, p < 0.5), nulliparity in 50% (95% CI 44–56, p < 0.6) in another
group of 978 of pregnant patients. The mean body mass index (BMI)
of mothers was 32.1 kg/m2 (95% CI 0.7–54, p < 0.3). The mean
gestational age at admission was 36 weeks (95% CI 34–37,
p < 0.001). Caesarean delivery occurred in 48% (95% CI 42–54,
p < 0.001), vaginal delivery in 26% (95% CI 20–34, p < 0.001),
singleton in 92% (95% CI 79–97, p < 0.09), twins in 9% (95% CI
2–26.5, p < 0.04), premature rupture of membranes in 14% (95% CI
7–29, p < 0.014), preterm labour in 25% (95% CI 4–74, p < 0.004),
preterm birth in 21% (95% CI 12–34, p < 0.003), pre‐eclampsia in
9.5% (95% CI 3–27.5, p < 0.03), placenta previa in 7.5% (95% CI
2–28, p < 0.1), abortion in 4% (95% CI 2–9, p < 0.001), postpartum
haemorrhage in 54.5 (95% CI 7–94, p < 0.001) of the pregnant
COVID‐19 confirmed cases (Table 4).
3.10 | Fetal characteristics and outcomes of
pregnant patients with confirmed COVID‐19
Fetal distress reported in 16% (95% CI 7–32, p = 0.046), fetal
tachycardia in 10% (95% CI 7.5–15, p < 0.99), neonatal death in 2.5%
(95% CI 1.5–6, p < 0.6), stillbirth in 4% (95% CI 1.5–10, p < 0.036),
LBW (<2500 g) in 25% (95% CI 16–37, p < 0.001), mean of 1 min
APGAR score was 9 (95% CI 8–10, p = 0.9), mean of 5 min APGAR
score was 10 (95% CI 9–10.7, p = 0.9), neonatal asphyxia in 4% (95%
CI 1.5–9, p = 0.8), vertical transmission in 5.3% (95% CI 13–16,
p = 0.3), neonatal symptoms was found among 33% (95% CI 13–62,
p < 0.001) of 579 cases, neonates with confirmed COVID‐19 were
8% (95% CI 4–16, p < 0.78) and COVID‐19 negative children were
68% (95% CI 57–78, p < 0.001). Breast feeding in 38% (95% CI
20–61, p < 0.001), formula feeding in 56% (95% CI 28.5–80,
p < 0.001), mixed feeding in 39% (95% CI 2.5–94, p < 0.001) of cases
were reported. SARS‐CoV‐2 reported to detect in 12% (95% CI 5–26,
p < 0.3) of placenta specimens, in 5% (95% CI 2–11, p < 0.26) of
breast milk, in 5.6% (95% CI 2–15, p < 0.8) of amniotic fluid, in 6%
(95% CI 2–12.5, p < 0.9) of umbilical cord and in 4.6% (95% CI
1.6–12.5, p < 0.5) of vaginal secretions (Table 4).
4 | DISCUSSION
This meta‐analysis described the characteristics of COVID‐19 in
pregnant patients in comparison with the non‐pregnant adult popu-
lation. In general, our meta‐analysis showed that pregnant patients
with COVID‐19 had similar clinical, laboratory and imaging charac-
teristics to non‐pregnant adult patients in the general population.
Pregnant women with COVID‐19 experience worse perinatal out-
comes comparing with pregnant women without COVID‐19. SARS‐
CoV‐2 is detected in conception products and breast milk that may
allow the vertical transmission of the virus to the fetus.
Based on a report by the CDC, most prevalent symptoms in
patients with COVID‐19 in the general population were cough (84%),
fever (80%), myalgia (63%), chills (63%), fatigue (62%), headache
(59%) and shortness of breath (57%).40 Our results revealed that
fever (75.5%) and cough (48.5%) were the most common clinical
symptoms observed in both pregnant women and non‐pregnant
patients with COVID‐19. They were followed by myalgia and chill in
pregnant women and dysgeusia and fatigue in non‐pregnant patients.
Fever and cough were also reported by other meta‐analyses as
the most common manifestations of COVID‐19 in pregnant
women.19,41,42 Based on our analysis, pregnant women with COVID‐
19 manifested fever with similar odds to non‐pregnant women with
COVID‐19; however, they were less likely to show cough, fatigue,
sore throat, headache and diarrhoea. The lower probability of com-
mon symptoms of COVID‐19 in pregnant women, shown by our
results and another meta‐analysis,19 suggests a more asymptomatic
course of the disease in pregnancy.
Our analysis showed that from every three pregnant patients
with COVID‐19, approximately one patient had pre‐existing comor-
bidities. The most common comorbidities were diabetes (including
gestational and non‐gestational diabetes) and bacterial co‐infection
in pregnant patients. History of diabetes was also more common in
pregnant women with COVID‐19 compared with non‐pregnant
women with the disease in a different meta‐analysis.19 Our results
showed that both bacterial and viral co‐infection were more preva-
lent among pregnant women than in non‐pregnant patients. These
findings can be related to the relative immunosuppression status due
to pregnancy as well as the immunocompromised state during
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SARS‐CoV‐2 infection. Co‐infection in pregnant women may be the
reason of the observed laboratory changes such as leucocytosis and
elevated CRP. They may also be linked with adverse pregnancy
outcomes such as preterm labour and birth since there are evidence
regarding this association.43 The mean of maternal BMI (32.1 kg/m2)
in this study suggests that a considerable number of pregnant pa-
tients with COVID‐19 were obese. It can be hypothesized that obese
patients are more probable to catch the disease in the hospital since
they are more possible to admit in the hospital due to obstetric
complications. Obesity is a risk factor for almost all pregnancy
complications and maternal death.44 It is also an independent prog-
nostic factor for the severity of COVID‐19.45 A report from the CDC
also indicated a high frequency of chronic lung disease, diabetes
mellitus and cardiovascular disease among pregnant patients with
COVID‐19.46 Regardless of the possible impairment of the immune
system in pregnancy, our results indicate that comorbidities likely
play a role in acquiring the infection and developing complications.
Our findings suggest that pregnant patients with COVID‐19
show similar imaging lesions with non‐pregnant patients. In contrast,
GGOs were more common than consolidation in pregnant women.
GOO was reported by another meta‐analysis as the most common
imaging finding in pregnant patients.41 In another study, clinical and
imaging parameters were retrospectively reviewed and compared
between pregnant patients and non‐pregnant patients with
COVID‐19. The results showed higher frequent consolidation
including mixed GGO with consolidation and complete consolidation
in the pregnant group compared to the non‐pregnant adults that are
inconsistent with our results which may be due to a smaller number
of patients in their study.47
In a large group of patients with COVID‐19 from the general
population, the most prevalent laboratory findings were increased
CRP (73.6%), decreased albumin (62.9%), increased erythrocyte
sedimentation rate (61.2%), decreased eosinophils (58.4%), increased
interleucin‐6 (53.1%), lymphopenia (47.9%) and increased lactate













Leucocytes 3.5–9.5 (� 10⁹
per L)
6 (5–7.2) 10,268 81 8 (7.2–8.8) 294 5
Increased 14 (%) 27 (%)
Decreased 25.5 (%) 25 (%)
Neutrophils 1.8–6.3 (� 10⁹
per L)
4.3 (3.5–8.5) 9742 53 6.6 (4.6–8.2) 10 2
Increased ‐ 70%
Lymphocytes 1.1–3.2 (� 10⁹
per L)
1.12 (0.95–1.3) 16,231 71 1.25 (0.5–1.7) 317 9
Decreased 62.5 (%) 64 (%)
Platelets 125–350 (� 10⁹
per L)
185 (179–198) 8456 46 ‐ ‐ ‐
Decreased 12.5 (%) 18 (%) 47 5
Increased 28 (%) ‐
C‐reactive proteina 0–0.5 (mg/L) 29 (16.7–42.5) 1455 29 11 (5–16) 316 8
Increased 81 (%) 52 (%)
Alanine
aminotransferase
20–60 IU/L 28.4 (28.3–28.5) 9958 64 31.5 (16–65) 24 5
Aspartate
aminotransferase
29–33IU/L 37.5 (31–44) 9803 62 29 (9–50) 24 5
Total bilirubin 0.1–1.2 (mg/dl) 0.6 (0.2–1.3) 91 2 0.4 (0.3–0.5) 58 3
Albumin 35‐55 g/L 37 (35.6–38) 8227 40 29 (22–36) 64 3
D‐dimer <0.4 mcg/ml 2.5 (0.8–5.5) 7407 48 3.5 (1.4–5.5) 27 3
Na 135–145 mmol/
L
140.8 (140.7–140.9) 6403 20 139 (137–140) 6 3
K 3.5–5.0 mmol/L 4.1 (4–4.2) 6171 20 3.7 (3–5) 6 3
aIncreased and decreased refer to values above or below the normal range, respectively. Some normal ranges can be different in the different age and sex
groups.
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Medical comorbidities 33 (20–48) 21 8172 71 <0.001
History of caesarean delivery 17 (9.6–28) 6 723 17 0.3
Number of gravidity* 4.3 (3.2–5.5) 15 562 0 0.7
History of parity 46 (40–52) 16 864 0 0.5
Nulliparity 50 (44–56) 9 978 0 0.6
Maternal BMI (kg/m2)* 32.1 (0.7–54) 14 764 16 0.3
Gestational age at admission (mean of
weeks)
36 (34–37) 31 869 85 <0.001
Caesarean delivery 48 (42–54) 57 8141 88 <0.001
Vaginal delivery 26 (20–34) 39 7937 96 <0.001
Preterm birth 21 (12–34) 18 896 64 0.003
Preterm labour 25 (4–74) 6 576 82 0.004
Abortion 4 (2–9) 9 1292 75 <0.001
PROM 14 (7–29) 13 456 62 0.014
Placenta previa 7.5 (2–28) 6 564 56 0.1
Pre‐eclampsia 9.5 (3–27.5) 7 812 65 0.03
Postpartum haemorrhage 54.5 (7–94) 8 564 88 <0.001
Singleton 92 (79–97) 12 654 44 0.09
Twins 9 (2–26.5) 8 456 59 0.04
Neonatal death 2.5 (1.5–6) 18 2152 0 0.6
Stillbirth 4 (1.5–10) 21 989 47 0.036
Low birth weight 25 (16–37) 22 481 69 <0.001
Fetal tachycardia 10 (7.5–15) 5 262 0 0.99
Fetal distress 16 (7–32) 12 795 58 0.046
1 min APGAR score* 9 (8–10) 16 1364 0 0.9
5‐min APGAR score* 10 (9‐10.7) 16 563 0 0.9
Neonatal asphyxia 4 (1.5‐9) 13 459 0 0.8
NICU admission 17 (11–25) 25 6943 85 <0.001
Vertical transmission 5.3 (13–16) 4 563 19 0.3
SARS‐CoV‐2 confirmed neonates 8 (4–16) 17 5593 0 0.78
Symptomatic neonates 33 (13–62) 15 579 79 <0.001
Breastfeeding 38 (20‐61) 13 456 84 <0.001
Formula feeding 56 (28.5–80) 9 342 82 <0.001
Mixed feeding 39 (2.5–94) 5 231 81 <0.001
SARS‐CoV‐2 found in placenta 12 (5–26) 11 364 7 0.3
SARS‐CoV‐2 found in breast milk 5 (2–11) 18 789 18 0.26
SARS‐CoV‐2 found in amniotic fluid 5.6 (2–15) 13 968 0 0.8
SARS‐CoV‐2 found in umbilical cord 6 (2–16.5) 9 324 0 0.9
SARS‐CoV‐2 found in vaginal secretions 4.6 (1.6–12.5) 8 253 0 0.5
Abbreviations: BMI, Body Mass Index; PROM, premature rupture of the membrane; NICU, neonatal intensive care unit; SARS‐CoV‐2, severe acute
respiratory syndrome coronavirus 2.
*Number of gravidity, maternal BMI, gestational age at admission, 1‐min APGAR score and 5‐min APGAR score are reported as mean. Other variables
are reported as proportions.
**Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity.
***A low p‐value (<0.05) is consistent with high heterogeneity.
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dehydrogenase (LDH) (46.2%).48 Leucopenia, lymphopenia, increased
LDH, CRP and ferritin were also the most common laboratory signs
among patients with COVID‐19 in another study.49 Compared with
non‐pregnant patients with COVID‐19 in previous studies and our
results, pregnant patients had similar changes of laboratory values
such as altered leucocyte and platelet counts (increased or
decreased), elevated levels of CRP, and D‐Dimer. The most common
laboratory findings in pregnant patients were in turn neutrophilia,
lymphopenia and raised CRP. Pregnant women had a higher pro-
portion of leucocytosis and thrombocytopenia, but a lower
proportion of elevated CRP comparing with non‐pregnant patients.
D‐Dimer levels were elevated in both groups, but were higher in
pregnant women (3.5 mcg/ml vs. 2.5 mcg/ml). Lymphopenia and
raised CRP were most commonly reported by other meta‐analyses of
pregnant patients.19,41 Somehow consistent with our findings,
another study reported that elevated leucocyte and neutrophil
counts were more common in pregnant patients comparing with non‐
pregnant adults. In the same study, no significant difference was
observed for lymphopenia between groups.47 The findings of another
study, more consistent with our results, reported elevated inflam-
matory markers such as WBC, neutrophil, CRP, procalcitonin and
D‐dimer were significantly higher in pregnant women, whereas mean
F I GUR E 2 Meta‐analysis forest plot, association of caesarean delivery in COVID‐19 pregnant women (case) and COVID‐19 non‐pregnant
women (control)
F I GUR E 3 Meta‐analysis forest plot, association of history of low birth weight (<2500 gr) in COVID‐19 pregnant women (case) and
COVID‐19 non‐pregnant women (control)
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lymphocyte percentage was lower than in non‐pregnant women.50
Physiologic alterations in laboratory values during pregnancy may
influence the interpretation of the values of pregnant women with
COVID‐19. Elevated leucocyte counts, particularly neutrophil count,
lymphocytopenia and thrombocytopenia are expected changes in
pregnant women.51 Furthermore, CRP values have been shown to be
elevated in pregnant women than non‐pregnant persons and may
further elevate during labour.52
In our meta‐analysis, the CFR for non‐pregnant adult patients
with COVID‐19 was 6.4%. Reports from different populations on
COVID‐19 CFR varied from 0 to 20%; however, the estimated overall
CFR was close to our study around 4%.53 In women infected by
SARS‐CoV‐1, the mortality rate appeared higher in those affected in
pregnancy compared with non‐pregnant women.14,54 The CFR for all
reported mortality cases of pregnant women due to SARS and MERS
were 15% and 27%, respectively.55 In the present meta‐analysis,
mortality from all‐cause in 2660 pregnant patients with COVID‐19
was 11.3%, which was markedly higher than 0.1% in another meta‐
analysis of 11,580 women.19 Various factors may be the source of the
observed difference such as high heterogeneity of the values in the
two studies (I2: 82% in the current study and I2: 80.2% in the second
study). Moreover, a significant proportion of some of the known risk
factors for maternal mortality was observed in our study. History of
medical comorbidities, obesity, gravidity and prior caesarean delivery
are maternal characteristic that were shown to be predictors of
maternal death.56
The most common obstetric outcomes based on our analysis
were postpartum haemorrhage, caesarean delivery, preterm labour
and preterm birth, respectively. Compared to women without
COVID‐19, preterm birth, caesarean delivery and LBW were more
probable in women with COVID‐19 and low or absent heterogeneity
were observed between studies. Higher odds of preterm birth
(OR = 3.01) in women with COVID‐19 compared to women without
the disease was reported by another meta‐analysis. They did not find
a difference for other maternal outcomes between groups.19 Preterm
delivery and birth weight did not show a significant association with
COVID‐19 in pregnant women in another meta‐analysis and they
reported a lack of between‐study heterogeneity (I2 = 0%).21
Caesarean delivery in our meta‐analysis occurred in almost half of
the patients. It was also shown to be higher by another meta‐analysis
(pooled proportion of 89%).42 Indications for the caesarean section
were not clear in most of the reports to show if they were due to
medical indications. In this context, a systematic review of the
pregnant COVID‐19 cases reported a high proportion of preterm
birth by caesarean delivery. Among cases with the available in-
dications for caesarean delivery, 55.9% was due to COVID‐19
pneumonia.27 Therefore, there is an urgent need to address these
issues. Higher proportions of comorbidities in pregnant patients
could have predisposed them to elevated risk for pregnancy com-
plications in addition to a higher risk for incidence and severity of the
COVID‐19. Inconsistent with the current study, a large‐scale cohort
observed no significant difference in pregnancy complications among
patients with SARS‐CoV‐2 infection and pregnant women without
infection.20 Neonatal intensive care unit (NICU) admission was
shown to have higher odds (OR 3.13) in neonates of pregnant pa-
tients with COVID‐19 than neonates born to patients without
COVID‐19 in another meta‐analysis.17
Some reports showed no evidence of vertical transmission and all
samples of neonates including throat swab, amniotic fluid, cord blood
and breast milk were negative.57–59 Conversely, there are reports on
the vertical transmission of the COVID‐19.22–25 The possibility of
this type of transmission is still under debate and strong evidence is
lacking to support this type of transmission.57–59 Real‐time poly-
merase chain reaction (RT‐PCR) of nasopharyngeal or anal swabs of
infants born to infected mothers was reported.22,24 Elevated SARS‐
CoV‐2 IgM and IgG were also observed in the neonates of mothers
with COVID‐19, while the results of the RT‐PCR were negative for
SARS‐CoV‐2.60,61 This result suggests that elevated anti‐SARS‐CoV‐
2 antibody is not a strong evidence for vertical transmission due to
the possible transfer from mother to infant. The results from our
study support that there is a low possibility of vertical transmission in
agreement with the results of other meta‐analyses.62 In our study,
SARS‐CoV‐2 was detected in breast milk and all conception products,
although with low proportion, suggest them as a route for viral
transmission. Other studies reported consistent findings regarding
the presence of SARS‐CoV‐2 in conception products.25,62 Based on
our results, the pooled proportion of positive SARS‐CoV‐2 in
placental specimens was almost twice than with other specimens.
ACE2 is strongly expressed in maternal–fetal interface involving the
placenta and decidua.63 Therefore, it can be hypothesized that the
virus can invade and damage the placenta and increase placental
permeability. It may possibly lead to placenta insufficiency and some
of the obstetric complications that were reported in women with
COVID‐19 such as abortion, LBW or preterm birth. Based on the
suggestive evidence for direct placenta invasion, caesarean delivery
may not significantly decrease the risk of vertical transmission. In this
regard, the neonates of the mothers with COVID‐19 were assessed
for acquiring the infection. It was reported that the risk was low and
caesarean delivery and breastfeeding did not increase the risk.64
Moreover, in most studies, infants with positive test results for SARS‐
CoV‐2 were asymptomatic or developed mild symptoms.22,60,61,64
In conclusion, this meta‐analysis provided valuable information
regarding COVID‐19 in the pregnant women and clarified that they
are at a potential higher risk for pregnancy complications. We
emphasize that both patients and their families are needed to be
educated about preventive measures for SARS‐CoV‐2 infection and
closely follow‐up for the development of signs and symptoms of the
disease.
4.1 | Limitations
Several limitations exist for this study. Publication bias and study
heterogeneity are unavoidable in this type of study; therefore, it
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should be considered when interpreting the final data set. Further,
this study may overestimate disease severity due to lack of screening
of asymptomatic or mildly symptomatic individuals and subsequent
publication bias related to these factors. Journal bias is another issue
facing those who carry out meta‐analysis, yet it does not usually
affect the general conclusions. Also, the possibility of the occurrence
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